Bo Cumbo, AavantiBio CEO
Scoop: A small gene therapy biotech, flush with ex-Sarepta and bluebird leaders, guts CMC
En route to entering the clinic with its first AAV-based gene therapy for a rare neuromuscular disease, AavantiBio has let go of 30 employees, …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
